Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$2.60 USD
-0.05 (-1.89%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $2.59 -0.01 (-0.38%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Brokerage Reports
Galectin Therapeutics Inc. [GALT]
Reports for Purchase
Showing records 21 - 40 ( 107 total )
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Published Data Show Belapectin Enhances Cancer Immunotherapy Response
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Galectin Running Full Steam Ahead With Belapectin in Three Clinical Trials; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
3Q20 Recap: Innovative Phase 2b/3 NASH-RX Study Continues Long Climb Towards Full Enrollment; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Final Program for Our Fourth Annual Virtual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
With NASH-RX Trial Underway, Investors Need Patience for Interim Analysis Expected in 2Q23; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Director Joel Lewis Takes the Reins as CEO as Dr. Shlevin Retires; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
2Q Recap: Looking Forward to the Interim Analysis of the Phase 2b/3 NASH-RX Trial; Raise PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
4Q19 Recap: Confident in Start of Phase 3 Cirrhotic NASH Trial in 2Q20; PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
3Q19 NASH-RX Start Delayed by 3 Months But Our Thesis Remains Unchanged; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Final Program for Our Third Annual NASH Investor Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Program for Our Third Annual NASH Investor Conference, October 21, New York
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
2Q19 Phase 3 NASH-RX Ready to Go, Just Awaiting Final OK from FDA; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Phase 3 NASH-RX Protocol in Cirrhotic NASH Submitted to FDA; Initiation Expected in 4Q19; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
With Successful Rights Offering, Sole Focus Remains Initiating Phase 3 in 3Q19; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
1Q19 Recap; We Believe the Rights Offering Will Be Successful; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
With the Phase 3 Design Set, the Rights Offering Is Underway; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Rights Offering Boosts Our Confidence; We See a Pivotal Readout Likely in 1Q22: Adjust PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
NASH Splash No. 5: The STELLAR-4 Failure Is No Big Surprise to Us
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galectin Therapeutics Inc.
Industry: Medical - Drugs
Galectin Cleans up Balance Sheet and Related Covenants to Better Attract Outside Parties
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E